Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This phase 3 trial is testing whether adding an experimental drug called SHR-1501 to the standard BCG therapy can improve outcomes for people with a high-risk form of bladder cancer that has not spread into the muscle wall. Participants must have had all visible tumors removed be…

This phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…

This phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…

This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the ne…